Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDH1R132H Vaccine and Avelumab in Recurrent Glioma
NCT03893903Phase 1Completed
- Sponsor
- German Cancer Research Center
- Start
- Oct 2018
- Primary completion
- Sep 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of IDH1R132H peptide vaccine in malignant glioma (3 arms), sponsored by German Cancer Research Center. Primary endpoint: Regime Limiting Toxicity at 43 weeks. Started Oct 2018; status: completed.
02
Drugs
IDH1R132H peptide vaccine
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT03893903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03893903.